Cargando…

Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus

BACKGROUND: Recent clinical trials of new glucose-lowering treatments have drawn attention to the importance of hospitalization for heart failure as a complication of diabetes mellitus. However, the epidemiology is not well described, particularly for type 1 diabetes mellitus. We examined the incide...

Descripción completa

Detalles Bibliográficos
Autores principales:	McAllister, David A., Read, Stephanie H., Kerssens, Jan, Livingstone, Shona, McGurnaghan, Stuart, Jhund, Pardeep, Petrie, John, Sattar, Naveed, Fischbacher, Colin, Kristensen, Soren Lund, McMurray, John, Colhoun, Helen M., Wild, Sarah H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287897/ https://www.ncbi.nlm.nih.gov/pubmed/29950404 http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034986

Ejemplares similares

Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015
por: Read, Stephanie H., et al.
Publicado: (2019)

Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013
por: Read, Stephanie H., et al.
Publicado: (2016)

Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012–2014): a population-based observational study
por: Walker, Jeremy, et al.
Publicado: (2017)

Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study
por: Bell, Samira, et al.
Publicado: (2017)

Cohort profile: the Scottish Diabetes Research Network national diabetes cohort – a population-based cohort of people with diabetes in Scotland
por: McGurnaghan, Stuart J., et al.
Publicado: (2022)

Development and validation of a cardiovascular risk prediction model in type 1 diabetes
por: McGurnaghan, Stuart J., et al.
Publicado: (2021)

Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis
por: McGurnaghan, S., et al.
Publicado: (2018)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

Microvascular disease in diabetes and severe COVID-19 outcomes – Authors' reply
por: Colhoun, Helen M, et al.
Publicado: (2021)

Use of personalised risk-based screening schedules to optimise workload and sojourn time in screening programmes for diabetic retinopathy: A retrospective cohort study
por: Ochs, Andreas, et al.
Publicado: (2019)

Effect of Socioeconomic Status on Mortality Among People With Type 2 Diabetes: A study from the Scottish Diabetes Research Network Epidemiology Group
por: Walker, Jeremy J., et al.
Publicado: (2011)

Ethnic Differences in Glycaemic Control in People with Type 2 Diabetes Mellitus Living in Scotland
por: Negandhi, Preeti H., et al.
Publicado: (2013)

Amputation-free survival in 17,353 people at high risk for foot ulceration in diabetes: a national observational study
por: Vadiveloo, Thenmalar, et al.
Publicado: (2018)

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
por: Jhund, Pardeep S, et al.
Publicado: (2016)

Glycaemic control trends in people with type 1 diabetes in Scotland 2004–2016
por: Mair, Colette, et al.
Publicado: (2019)

Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol
por: Butterly, Elaine, et al.
Publicado: (2022)

Association is not causation: treatment effects cannot be estimated from observational data in heart failure
por: Rush, Christopher J, et al.
Publicado: (2018)

Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017
por: O’Reilly, Joseph E., et al.
Publicado: (2020)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Large socioeconomic gap in period life expectancy and life years spent with complications of diabetes in the Scottish population with type 1 diabetes, 2013–2018
por: Höhn, Andreas, et al.
Publicado: (2022)

Mapping activities on climate and health to the essential public health operations (EPHO)
por: McGurnaghan, P, et al.
Publicado: (2023)

Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis
por: Curtain, James P, et al.
Publicado: (2023)

Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland
por: Jeyam, Anita, et al.
Publicado: (2021)

Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study
por: McKeigue, Paul M., et al.
Publicado: (2021)

Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
por: Butt, Jawad H, et al.
Publicado: (2023)

The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes
por: Höhn, Andreas, et al.
Publicado: (2021)

Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus
por: Colombo, Marco, et al.
Publicado: (2019)

Genome-wide aggregated trans-effects on risk of type 1 diabetes: A test of the “omnigenic” sparse effector hypothesis of complex trait genetics
por: Iakovliev, Andrii, et al.
Publicado: (2023)

What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?
por: Cannon, Jane A, et al.
Publicado: (2015)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Reduced Incidence of Lower-Extremity Amputations in People With Diabetes in Scotland: A nationwide study
por: Kennon, Brian, et al.
Publicado: (2012)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland
por: McGurnaghan, Stuart J, et al.
Publicado: (2021)

Stress Hyperglycaemia in Hospitalised Patients and Their 3-Year Risk of Diabetes: A Scottish Retrospective Cohort Study
por: McAllister, David A., et al.
Publicado: (2014)

Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study
por: McKeigue, Paul M., et al.
Publicado: (2020)

Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study
por: McKeigue, Paul M., et al.
Publicado: (2021)

Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes
por: Colombo, Marco, et al.
Publicado: (2020)

Achieved Levels of HbA(1c) and Likelihood of Hospital Admission in People With Type 1 Diabetes in the Scottish Population: A study from the Scottish Diabetes Research Network Epidemiology Group
por: Govan, Lindsay, et al.
Publicado: (2011)

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
por: Sattar, Naveed, et al.
Publicado: (2016)

Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
por: Sattar, Naveed, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hjmravjqnaibh3cctvskqdbbcj